BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 34768921)

  • 1. PDK1 Inhibitor BX795 Improves Cisplatin and Radio-Efficacy in Oral Squamous Cell Carcinoma by Downregulating the PDK1/CD47/Akt-Mediated Glycolysis Signaling Pathway.
    Pai S; Yadav VK; Kuo KT; Pikatan NW; Lin CS; Chien MH; Lee WH; Hsiao M; Chiu SC; Yeh CT; Tsai JT
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768921
    [No Abstract]   [Full Text] [Related]  

  • 2. CD47-SIRPα Signaling Induces Epithelial-Mesenchymal Transition and Cancer Stemness and Links to a Poor Prognosis in Patients with Oral Squamous Cell Carcinoma.
    Pai S; Bamodu OA; Lin YK; Lin CS; Chu PY; Chien MH; Wang LS; Hsiao M; Yeh CT; Tsai JT
    Cells; 2019 Dec; 8(12):. PubMed ID: 31861233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
    Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
    Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BX795, a TBK1 inhibitor, exhibits antitumor activity in human oral squamous cell carcinoma through apoptosis induction and mitotic phase arrest.
    Bai LY; Chiu CF; Kapuriya NP; Shieh TM; Tsai YC; Wu CY; Sargeant AM; Weng JR
    Eur J Pharmacol; 2015 Dec; 769():287-96. PubMed ID: 26607461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis.
    Mohapatra P; Shriwas O; Mohanty S; Ghosh A; Smita S; Kaushik SR; Arya R; Rath R; Das Majumdar SK; Muduly DK; Raghav SK; Nanda RK; Dash R
    JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33434185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malic Enzyme 1 Is Associated with Tumor Budding in Oral Squamous Cell Carcinomas.
    Nakashima C; Kirita T; Yamamoto K; Mori S; Luo Y; Sasaki T; Fujii K; Ohmori H; Kawahara I; Mori T; Goto K; Kishi S; Fujiwara-Tani R; Kuniyasu H
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. San-Zhong-Kui-Jian-Tang Exerts Antitumor Effects Associated With Decreased Cell Proliferation and Metastasis by Targeting ERK and the Epithelial-Mesenchymal Transition Pathway in Oral Cavity Squamous Cell Carcinoma.
    Hsu PY; Chen JL; Kuo SL; Wang WL; Jan FW; Yang SH; Yang CY
    Integr Cancer Ther; 2022; 21():15347354221134921. PubMed ID: 36404765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer-derived IgG involved in cisplatin resistance through PTP-BAS/Src/PDK1/AKT signaling pathway.
    Wang LM; Gan YH
    Oral Dis; 2021 Apr; 27(3):464-474. PubMed ID: 32730654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
    Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
    Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bromodomain-containing protein 4 inhibition improves the efficacy of cisplatin and radiotherapy in oral squamous cell carcinoma by suppressing programmed cell death-ligand 1 expression.
    Ren J
    Basic Clin Pharmacol Toxicol; 2024 Feb; 134(2):272-283. PubMed ID: 38014458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitrate increases cisplatin chemosensitivity of oral squamous cell carcinoma via REDD1/AKT signaling pathway.
    Feng Y; Cao X; Zhao B; Song C; Pang B; Hu L; Zhang C; Wang J; He J; Wang S
    Sci China Life Sci; 2021 Nov; 64(11):1814-1828. PubMed ID: 34542810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma.
    Zhao B; Huang Z; Qin Z; Li Y; Wang T; Wang L; Zhou W; Yu C; Wang X; Yang S; Fan Y; Xiang R
    Cell Physiol Biochem; 2019; 53(1):141-156. PubMed ID: 31237760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PDK1 Inhibitor GSK-470 Exhibits Potent Anticancer Activity in a Pheochromocytoma PC12 Cell Tumor Model via Akt/mTOR Pathway.
    Zhang X; Zhong S
    Anticancer Agents Med Chem; 2020; 20(7):828-833. PubMed ID: 32188393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HOXA1 silencing inhibits cisplatin resistance of oral squamous cell carcinoma cells via IκB/NF-κB signaling pathway.
    Zhu R; Mao Y; Xu X; Li Y; Zheng J
    Anticancer Drugs; 2024 Jul; 35(6):492-500. PubMed ID: 38477942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of PER2 Promotes Tumor Progression by Enhancing Glycolysis via the Phosphatidylinositol 3-Kinase/Protein Kinase B Pathway in Oral Squamous Cell Carcinoma.
    Long W; Gong X; Yang Y; Yang K
    J Oral Maxillofac Surg; 2020 Oct; 78(10):1780.e1-1780.e14. PubMed ID: 32615095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3β signaling networks promotes chemoresistance, invasion/migration and stemness via expression of CD44 variants (v4 and v6) in oral cancer.
    Kashyap T; Pramanik KK; Nath N; Mishra P; Singh AK; Nagini S; Rana A; Mishra R
    Oral Oncol; 2018 Nov; 86():234-243. PubMed ID: 30409306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blocking circ-CNST suppresses malignant behaviors of osteosarcoma cells and inhibits glycolysis through circ-CNST-miR-578-LDHA/PDK1 ceRNA networks.
    Hu R; Chen S; Yan J
    J Orthop Surg Res; 2021 May; 16(1):300. PubMed ID: 33962616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined inhibition of pyruvate dehydrogenase kinase 1 and lactate dehydrogenase a induces metabolic and signaling reprogramming and enhances lung adenocarcinoma cell killing.
    Zhou Y; Guo Y; Ran M; Shan W; Granchi C; Giovannetti E; Minutolo F; Peters GJ; Tam KY
    Cancer Lett; 2023 Nov; 577():216425. PubMed ID: 37805163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting CD47 Inhibits Tumor Development and Increases Phagocytosis in Oral Squamous Cell Carcinoma.
    Ye XJ; Yang JG; Tan YQ; Chen XJ; Zhou G
    Anticancer Agents Med Chem; 2021; 21(6):766-774. PubMed ID: 32748759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bcl-xL expression and regulation in the progression, recurrence, and cisplatin resistance of oral cancer.
    Alam M; Mishra R
    Life Sci; 2021 Sep; 280():119705. PubMed ID: 34111459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.